Document:

<PAGE>
                                                                   EXHIBIT 10.34
<TABLE>
<S><C>
===================================================================================================================================
                                                                    1. CONTRACT ID NO.                               PAGE OF PAGES
     AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT                N01-HB-07148                                    1       3
-----------------------------------------------------------------------------------------------------------------------------------
2. AMENDMENT/MODIFICATION NO.     3. EFFECTIVE DATE        4. REQUISITION/PURCHASE REQ. NO.         5. PROJECT NO. (If applicable)
          Five (5)                   See Block 16C.                      N/A
-----------------------------------------------------------------------------------------------------------------------------------
6. ISSUED BY                  CODE                        7. ADMINISTERED BY (If other than Item 6)            CODE
                                   --------------                                                                   --------------
National Institutes of Health                             BDR Contracts Section, COB, DEA, NHLBI
National Heart, Lung, and Blood Institute                 AIIN: 268907148
6701 Rockledge Drive (RKL2), MSC 7902                     OMB No. 0990-0115
Bethesda, MD 20892-7902
-----------------------------------------------------------------------------------------------------------------------------------
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)     (X) 9A. AMENDMENT OF SOLICITATION NO.
                                                                                ---
                                                                                    -----------------------------------------------
                                                                                    9B. DATED (SEE ITEM 13)
Gen-Probe, Inc.
10210 Genetic Center Drive                                                       --------------------------------------------------
San Diego, California 92121-4362                                                    10A. MODIFICATION OF CONTRACT/ORDER
                                                                                         NO.
                                                                                             N01-HB-07148
                                                                                (X) -----------------------------------------------
--------------------------------------------------------------------------------    10B. DATED (SEE ITEM 13)
CODE                                    FACILITY CODE                                        January 1, 2000
-----------------------------------------------------------------------------------------------------------------------------------
                                        11. THIS ITEM APPLIES TO AMENDMENTS OF SOLICITATIONS
-----------------------------------------------------------------------------------------------------------------------------------
[ ] The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers
                                                                        [  ] is extended, [  ] is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of
the following methods:

(a) By completing Items 8 and 15, and returning ___ copies of the amendment; (b) By acknowledging receipt of this amendment on each
copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment
numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE
SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted,
such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this
amendment, and is received prior to the opening hour and date specified.
-----------------------------------------------------------------------------------------------------------------------------------
12. ACCOUNTING AND APPROPRIATION DATA (If required)
Doc. No. 300N1HB07148A     DUNS 115337123     EIN: 1-33-0044608-A2
-----------------------------------------------------------------------------------------------------------------------------------
                                  13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,
                                      IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
-----------------------------------------------------------------------------------------------------------------------------------
[X]   A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT
----     ORDER NO. IN ITEM 10A.

-----------------------------------------------------------------------------------------------------------------------------------
      B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,
         appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

-----------------------------------------------------------------------------------------------------------------------------------
     C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
 X   FAR 1.602-1
-----------------------------------------------------------------------------------------------------------------------------------
     D. OTHER (Specify type of modification and authority)

-----------------------------------------------------------------------------------------------------------------------------------
E. IMPORTANT: Contractor [ ] is not, [X] is required to sign this document and return 2 copies to the issuing office.
-----------------------------------------------------------------------------------------------------------------------------------
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter
    where feasible.)

PURPOSE: To extend the contract eighteen (18) months without additional funding.

AMOUNT: $7,752,879 (UNCHANGED)

CONTRACT TYPE: Cost Reimbursement (Unchanged) EXPIRATION DATE: June 30, 2004 (CHANGED)

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains
unchanged and in full force and effect.
-----------------------------------------------------------------------------------------------------------------------------------
15A. NAME AND TITLE OF SIGNER (Type or print)               16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

  Henry L. Nordhoff, President & CEO                                              Lynda A. Bindseil
-----------------------------------------------------------------------------------------------------------------------------------
15B. CONTRACTOR/OFFEROR                 15C. DATE SIGNED    16B. UNITED STATES OF AMERICA                         16C. DATE SIGNED

   /s/ HENRY L. NORDHOFF                     4-FEB-02       BY /s/ LYNDA A. BINDSEIL                              2/7/02
   ----------------------------------------                    ----------------------------------------
   (Signature of person authorized to sign)                    (Signature of Contracting Officer)
-----------------------------------------------------------------------------------------------------------------------------------
NSN 7540-01-152-8070                                         30-105                                   STANDARD FORM 30 (REV. 10-83)
PREVIOUS EDITION UNUSABLE                                                                                         Prescribed by GSA
                                                                                                                FAR (48 CFR) 53.243
</TABLE>
<PAGE>

Gen-Probe, Inc.
Contract N01-HB-07148
Modification No. 5

THE GOVERNMENT AND THE CONTRACTOR MUTUALLY AGREE AS FOLLOWS:

1)    ARTICLE B.2. ESTIMATED COST, paragraphs a. and d. are hereby replaced as
      follows:

      "a.   This is a cost-sharing contract. The total estimated cost of
            performing the work under this contract is $19,552,879. For further
            provisions regarding the specific cost-sharing arrangement, see
            ARTICLE B.4. ADVANCE UNDERSTANDINGS."

      "d.   It is estimated that the amount currently allotted will cover
            performance of the contract through June 30, 2004."

2)    ARTICLE B.4. ADVANCE UNDERSTANDINGS, paragraph c. is revised and replaced
      as follows:

      "c.   COST SHARING

      (1)   This is a cost-sharing contract. Monies shall be provided for the
            total cost of performance from the National Institutes of Health,
            National Heart, Lung, and Blood Institute and Gen-Probe
            Incorporated.

      (2)   The Government shall provide monies in an amount not to exceed
            $7,752,879. The Contractor's share is estimated at $11,800,000 OR
            60.35% of the total estimated cost set forth in ARTICLE B.2.
            ESTIMATED COST, paragraph a.

      (3)   The Contractor shall maintain records of all contract costs
            (including costs claimed by the Contractor as being its share) and
            such records shall be subject to the Audit and Records clause of the
            General Clauses.

      (4)   Costs contributed by the Contractor shall not be charged to the
            Government under any other contract, grant, or cooperative agreement
            (including allocation to other grants, contracts, or cooperative
            agreements as part of an independent research and development
            program). The Contractor shall report the organization's share of
            the costs on its invoices to the Government as referenced in ARTICLE
            B.4.d.(1)."

3)    ARTICLE F.1. DELIVERIES, paragraph a. is hereby replaced as follows:

      "a.   The items specified below as described in SECTION C, ARTICLE C.1.
            will be required to be delivered F.O.B. Destination as set forth in
            FAR 52.247-35, F.O.B. DESTINATION, WITHIN CONSIGNEES PREMISES (APRIL
            1984), and in accordance with and by the date(s) specified below:

                                   Page 2 of 3
<PAGE>

Gen-Probe, Inc.
Contract N01-HB-07148
Modification No. 5

<TABLE>
<CAPTION>
      Item     Description                              Quantity                      Delivery Schedule
      ----     -----------                              --------                      -----------------
<S>            <C>                                      <C>                           <C>
      (a)      Quarterly Reports w/progress chart       Original & 5 copies           Quarterly

      (b)      Annual Reports w/progress chart          Original & 5 copies           12/31/00, 12/31/01,
                                                                                      12/31/02, 12/31/03

      (c)      Draft Final Report                       2 copies                      05/19/04

      (d)      Final Report                             Original & 20 copies          06/30/04

      (e)      Contractor/CBER Related Documents        2 Copies                      See below

      (f)      Progress Report for Clinical Research    Original & 5 copies           12/31/00, 12/31/01,
                                                                                      12/31/02, 12131/03
                                                                                      06/30/04
</TABLE>

      In addition to quarterly and annual progress reports, the contractor shall
      make available to the government a copy of the progress chart related to
      the projected course of the workscope. Also, copies of documents related
      to negotiations between the contractor and CBER officials shall be
      submitted to the Project Officer within two weeks of said negotiations.
      This shall include preclinical and clinical protocols as well as
      information from the study."

                                  Page 3 of 3<PAGE>
                                                                   EXHIBIT 10.35

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                  CONFIDENTIAL

                                SUPPLY AGREEMENT

                                     between

                            Boehringer Mannheim GmbH
                             Sandhofer Strasse 116
                                 68305 Mannheim
                                     Germany
                        (hereinafter referred to as "BM")

                                       and

                             Gen-Probe Incorporated
                           10210 Genetic Center Drive
                                    San Diego
                                CA 92121-4362 USA
                    (hereinafter referred to as "GEN-PROBE")

<PAGE>

PREAMBLE

      GEN-PROBE desires to purchase from BM and BM desires to sell to GEN-PROBE
      certain raw materials for Transcription Mediated Amplification ("TMA")
      related diagnostic units.

      In order to provide for the supply of the Products to GEN-PROBE, both
      parties agree on the following:

SECTION 1 DEFINITIONS

1.1   "Products" shall mean those raw materials included in Categories A and B
      unless otherwise agreed by the parties in writing:

      CATEGORY A

            1.)   [***] reverse transcriptase; and

            2.)   [***] T7 RNA Polymerase.

      CATEGORY B

            1.)   deoxyribonucleotides (dGTP, dTTP, dATP, dCTP);

            2.)   ribonucleotides (ATP, CTP, GTP, UTP);

            3.)   [***]; and

            4.)   [***],

      in accordance with functional specifications and acceptance criteria as
      set forth in Attachment A hereto, for the Intended Use. Within thirty (30)
      days of the date of this Agreement, BM shall provide to Gen-Probe: (1) a
      description of each BM test method identified in Attachment A; and (2) the
      specifications for each Product identified by BM catalog number in
      Attachment A.

      With regard to T7 RNA Polymerase, the parties expect that the initial
      specification set forth in Attachment A will be modified by GEN-PROBE and
      mutually agreed upon within 180 days of the date of this Agreement. BM
      agrees not to unreasonably withhold consent to such modified specification
      for the T7 RNA Polymerase.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 1
<PAGE>

1.2   "Intended Use" shall mean the use of the Products by GEN-PROBE in
      connection with developing and producing Transcription-Mediated
      Amplification related diagnostic products wherein Products meeting the
      specifications set forth in Attachment A are appropriate for use.

1.3   "Affiliates" of either party shall mean any corporation, partnership
      organization which such party directly or indirectly controls, is
      controlled by or is under common control with. For the purpose of this
      Agreement, "Control" shall mean the holding of 50% or more of the voting
      stock or other ownership interest of the corporation or business entity
      involved.

1.4   "Transformed Clone" shall mean a [***] reverse transcriptase clone, which
      was originally provided by GEN-PROBE to BM, to the extent the original
      clone was modified or genetically transformed by BM, using BM's
      confidential know how, for the purpose of [***]. (The "Transformed Clone"
      includes [***].) GEN-PROBE acknowledges that it consented to and approved
      BM's modification of the original clone, using BM's confidential know how,
      for the purpose of [***] for GEN-PROBE's exclusive benefit.

SECTION 2 SUBJECT MATTER OF THE AGREEMENT

2.1   The subject matter of this Agreement is the terms and conditions for the
      supply of the Products by BM to GEN-PROBE.

2.2   The Products shall be manufactured and/or distributed by BM or its
      Affiliates and shall conform to the specifications and acceptance criteria
      set forth in Attachment A. No changes shall be made to the specifications
      and acceptance criteria without the prior written approval of both
      parties, which shall not be unreasonably withheld.

2.3   During the term of this Agreement GEN-PROBE shall purchase from BM and BM
      shall supply to GEN-PROBE the minimum percentage of the worldwide usage by
      GEN-PROBE for the Intended Use, as shown in Attachment C.

2.4   Gen-Probe shall, upon request by BM, provide documentation, reasonably
      satisfactory to BM, verifying compliance with Section 2.3.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 2
<PAGE>

2.5   BM shall not make any change to its processes or procedures which may
      alter any Product's stability or performance. BM shall provide notice of
      any proposed change in its processes or procedures in accordance with
      certified ISO procedures for change control applicable to in vitro
      diagnostic raw material. BM's notice shall include a full description of
      the proposed change. GEN-PROBE shall be provided with sufficient samples
      of any Product made by a process which will be subject to the proposed
      change to enable GEN-PROBE to determine that such Product(s) will meet
      specifications and will function in Gen-Probe's TMA products.

SECTION 3 TERMS OF DELIVERY

3.1   The Products shall be delivered F.O.B destination, priority shipment.

3.2   Each delivery shall be accompanied by a release certificate by the quality
      control laboratory of BM, confirming that the shipment conforms to the
      specifications and acceptance criteria set forth in Attachment A and
      setting forth the results of BM's quality control tests pursuant to the
      test methods described in Attachment A.

SECTION 4 PURCHASE PRICE

4.1   (a) Fixed Prices to be paid by GEN-PROBE for the Products are specified in
          Attachment B through the year 2004 and are contingent upon current
          specifications and acceptance criteria as described in Attachment A.

      (b) If acceptance criteria or specifications for the Products are changed
          at GEN-PROBE's request, the prices are subject to change to the extent
          necessary to compensate BM for such changes. The prices are also
          subject to change pursuant to Section 9.2 of this Agreement,
          concerning regulatory requirements.

                                     Page 3
<PAGE>

      (c) If, at any time after the first anniversary date of this Agreement,
          the U.S. Dollar - Deutsch Mark exchange rate (or the U.S. Dollar -
          Euro exchange rate, if applicable), is more than 15% higher or lower
          than the date existing on the date of this Agreement, then either
          party may request that revised prices be negotiated to reflect such
          change. The parties shall negotiate revised prices in good faith and
          each party shall be entitled to take into account the economic impact
          of the proposed change on its own interests. If despite good faith
          negotiations, new prices cannot be agreed upon within ninety (90) days
          following a request by either party, the party requesting the price
          revision may terminate this Agreement upon ninety (90) days written
          notice.

4.2   BM may, after the seventh (7th) anniversary of this agreement and subject
      to the restrictions in the next two (2) sentences, adjust the purchase
      prices in Attachment B to incorporate actual changes in the raw materials
      and labor costs associated with the manufacture of the Products. [***]. BM
      shall provide GEN-PROBE not less than one hundred and twenty (120) days
      prior written notice of any proposed increase in the purchase price of the
      Products. GEN-PROBE and BM agree to negotiate any such price changes in
      good faith and with the intent of seeking a mutually beneficial
      resolution. The increase in the price of any Product shall not exceed
      [***] of the prior year's purchase price for that Product.

4.3   Upon written request by a party, the other party shall provide
      documentation supporting any proposed price adjustment requested under the
      terms of this Agreement to a mutually agreeable certified public
      accountant who shall review the aforementioned documentation for
      supporting the price adjustment. The certified public accountant shall
      sign a secrecy agreement with the party providing the information and
      shall act regarding the provided information in accordance with such
      secrecy agreement. The certified public accountant shall only make a
      statement whether the provided documentation supports the proposed price
      adjustment or not.

4.4   The Product purchase price in any year shall be estimated by applying
      GEN-PROBE's purchase order pursuant to Section 7.1 for that year to the
      appropriate pricing tier schedule in Attachment B.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 4
<PAGE>

      If the amount of any Product actually purchased by GEN-PROBE in any year
      is more or less than that estimated and as a result a different pricing
      tier schedule applies to the amount actually purchased, then not later
      than sixty (60) days after the first anniversary and each anniversary
      thereafter, the parties shall reconcile the effect on the purchase price
      for that Product in the preceding year caused by any shortfall or overage
      in the total quantity of the Product actually purchased, and any payment
      due as a result of such reconciliation shall be made by the appropriate
      party within 30 days.

SECTION 5 PAYMENT

      GEN-PROBE shall pay each BM invoice for Product(s) within thirty (30) days
      of the date of invoice. BM will invoice GEN-PROBE no earlier than the date
      BM ships the Products described in the invoice to GEN-PROBE. Invoicing and
      payment shall be made in US dollars.

SECTION 6 FORECASTING PROCESS

6.1   GEN-PROBE has set forth its initial estimates of its anticipated purchase
      projection from BM in Attachment C. BM understands that these estimates
      are not binding, except for 1998, and do not establish any minimum amount
      of purchases by GEN-PROBE.

      For purposes of BM's long term manufacturing capacity planning, GEN-PROBE
      shall provide to BM annually by the last day of September, a revised
      projection of purchase volume for each of the succeeding three (3)
      calendar years or for the remaining period of the contract, whichever
      period is shorter. Each year BM and GEN-PROBE shall agree on the quantity
      of the Products to be delivered in the next year for any Product as to
      which GEN-PROBE ordered more than twice the projected amount for the
      preceding year. The lead time to adjust BM's manufacturing capacity to
      said quantity will be negotiated and agreed upon following agreement with
      the new projection. All such estimates shall be considered to be
      confidential and proprietary information of GEN-PROBE under this
      Agreement.

SECTION 7 PURCHASE ORDERS, DELIVERY PROCESS AND SECURITY OF SUPPLY

7.1   GEN-PROBE shall submit to BM by the last day of September of each year a
        purchase order of its requirements for the Products for the next
        succeeding year. Each of GEN-PROBE's purchase orders for the Products
        shall be in writing and shall constitute a binding obligation upon
        GEN-PROBE to accept and pay for a minimum of [***] of the quantities
        ordered. In conjunction with its annual purchase order, GEN-PROBE shall
        provide to BM, in writing, a

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 5
<PAGE>

      quarterly delivery schedule which identifies quantities, destinations, and
      approximate delivery dates.

      Furthermore, both parties will agree annually in December of each calendar
      year on adequate levels of safety stock and storage locations therefor to
      ensure the agreed upon terms of delivery are achieved. The parties agree
      that a significant portion of the safety stocks shall be maintained at
      GEN-PROBE's facility at San Diego, California and the balance at BM's
      facilities in the United States. As to any Products kept as safety stocks
      at Gen-Probe's facilities, BM shall provide the information described in
      Section 3.2 for such Products at the timof the delivery of those Products
      into the safety stock. GEN-PROBE shall not be obligated to pay for the
      safety stock Products except (1) upon use of such Products; (2) Pursuant
      to Section 13.4; or (3) To the extent that GEN-PROBE requests that more
      than a 90-day supply of Products be stored in San Diego as part of the
      safety stock.

      Additional provisions concerning the logistical arrangements for the
      safety stock and creation of the initial safety stock shall be agreed by
      the parties within 120 days of the date of this Agreement. It is the
      parties' present intent that the safety stock shall include an amount of
      each of the Products equal to GEN-PROBE's requirements for a six-month
      period.

7.2   Proposed additions to the agreed upon annual purchase quantities
      identified in the annual purchase order shall be submitted by GEN-PROBE in
      writing to BM.

      BM will use reasonable efforts to meet delivery times of ninety (90) days
      from date of receipt of quantity changes. Delivery dates for quantities
      outside of planned volumes will be negotiated at the time the written
      change request is received.

7.3   As compensation for BM's R&D expenses, GEN-PROBE has committed to purchase
      the Products and their stated amounts as set forth in Attachment C for the
      year 1998.

7.4   Gen-Probe and BM have previously entered into a material transfer
      agreement with respect to the transfer of [***] from GEN-PROBE to BM and
      certain research and development work by BM. The provisions of any prior
      material transfer agreement between the parties are hereby superseded with
      respect to use of the Transformed Clone and ownership and use of any
      intellectual property of BM reflected or incorporated in the Transformed
      Clone. All other provisions of the material transfer agreements shall
      remain in effect.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 6
<PAGE>

      BM shall be solely and exclusively entitled to use and make Transformed
      Clones. Notwithstanding the preceding sentence, GEN-PROBE may use the
      Transformed Clone in accordance with the provisions set forth below in
      this Section 7.4. GEN-PROBE shall not be entitled to use the Transformed
      Clone in any manner or on any terms other than those set forth below in
      this Section 7.4.

      Immediately following the signing of this Agreement, and from time-to-time
      thereafter if appropriate, BM shall deliver to GEN-PROBE examples of the
      Transformed Clone, which sample shall be treated as and kept confidential
      in accordance with paragraph 12 of this Agreement.

      (A)   USE OF THE TRANSFORMED CLONE BY GEN-PROBE DURING TERM OF AGREEMENT
            SO LONG AS BM IS ABLE TO SUPPLY GEN-PROBE WITH [***].

            During the term of this Agreement and so long as BM is able to
            supply GEN-PROBE with [***], GEN-PROBE agrees that it will not,
            without the prior express written consent of BM, do any of the
            following:

            (1)   [***]

            (2)   [***]

            (3)   [***]

            (4)   [***]

            (5)   [***]

            (6)   [***]

            During the term of this Agreement and so long as BM is able to
            supply GEN-PROBE with [***], GEN-PROBE may only use the Transformed
            Clone for the following specific purposes:

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 7
<PAGE>

            (1)   [***]

            (2)   [***]

            (3)   [***]

      (B) USE OF TRANSFORMED CLONE UPON FAILURE OF BM TO SUPPLY.

            In the event that BM fails to supply Gen-Probe with [***] in
            accordance with this Agreement, BM may use a third party supplier as
            necessary for securing the supply of [***]. The use of the
            aforementioned third party supplier by BM is subject to prior
            written consent by GEN-PROBE, which consent shall not unreasonably
            withheld. The third party shall sign a material transfer agreement
            with BM and with GEN-PROBE regarding the Transformed Clones which
            shall, among such other things as may be provided by BM, protect and
            preserve GEN-PROBE's rights in the Transformed Clone and GEN-PROBE's
            confidential materials and information. The Third Party shall
            receive the Transformed Clones and the know how with regard to [***]
            and shall return the Transformed Clones and the know how with regard
            to [***] to BM promptly after BM has become able to supply GEN-PROBE
            with [***]. If a third party supplier is not found by BM within
            three (3) months after the event of non-supply has occurred, then
            GEN-PROBE may, at its option, assign a third party supplier (which
            assignment is subject to prior written consent of BM, which consent
            shall not unreasonably withheld), or after seeking such a third
            party supplier may terminate this Agreement. The third party shall
            sign a material transfer agreement with BM and with GEN-PROBE
            regarding the Transformed Clones, shall receive the Transformed
            Clones and the know how with regard to [***] and shall return the
            Transformed Clones and the know how with regard to [***] to BM
            promptly after GEN-PROBE has had a reasonable opportunity to arrange
            for an alternative source of supply, not to exceed three years.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 8
<PAGE>

      (C) USE OF TRANSFORMED CLONE UPON TERMINATION OF AGREEMENT.

            After expiration or termination of this Agreement for any reason
            whatsoever, GEN-PROBE shall not use the Transformed Clone except
            upon obtaining a non-exclusive royalty bearing license from BM to
            use BM's know how incorporated in the transferred Transformed Clone
            and in the field and territory as set forth in the this Agreement in
            order to continue the manufacture of [***] required to manufacture
            TMA related diagnostic units by GEN-PROBE. (The foregoing sentence
            is subject to GEN-PROBE'S rights as set forth in subsection 7.4(B)
            above.)

            BM hereby grants an option to GEN-PROBE for such a license. The
            option shall be exercised by GEN-PROBE within sixty (60) days after
            expiration or termination of this Agreement. GEN-PROBE shall not use
            the know-how to be licensed by BM for purposes other than those
            described in this section and described in the license agreement.
            The royalty to be paid and the other terms and conditions of the
            license agreement shall be negotiated between BM and GEN-PROBE in
            good faith and shall not exceed commercially reasonable terms
            reflecting the terms charged by others for comparable technology.
            The annual royalties to be agreed upon, however, shall not exceed an
            annual amount of [***] of the Average of the Total Sales of the
            reverse transcriptase which average total sales shall be calculated
            of the calendar year of the termination or expiration and the two
            (2) preceding calendar years. If this Agreement is terminated within
            three (3) years upon execution of this Agreement, the annual
            royalties to be agreed upon shall not exceed an annual amount of
            [***] of the total sales of the reverse transcriptase in the
            calendar year preceding the termination. If this Agreement is
            terminated during the first calendar year upon execution the annual
            royalties to be agreed upon shall not exceed an annual amount of
            [***] of the total sales of the reverse transcriptase in the
            calendar year of termination.

            The license to be granted hereunder shall not authorize GEN-PROBE to
            conduct research to [***] in any GEN-PROBE development work.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 9
<PAGE>
SECTION 8 ACCEPTANCE

      GEN-PROBE shall, within thirty (30) days upon receipt of any shipment,
      inspect The Products to determine whether or not the delivery conforms to
      the applicable specifications and acceptance criteria. GEN-PROBE shall
      promptly give BM written notice of any failure or nonconformity. If
      GEN-PROBE fails to notify BM of any nonconformity of any Product within
      forty-five (45) days of receipt of the Product, GEN-PROBE shall be deemed
      to have accepted that Product as properly shipped and suitable for the
      Intended Use, except as to the stability specification for any Product, as
      to which GEN-PROBE shall be deemed to have accepted the Product if it does
      not give written notice within 30 days of discovery of the failure of the
      Product to meet the stability specification.

SECTION 9 REGULATORY MATTERS

9.1   A Design History File (DHF), Device Master Record (DMR), and Device
      History Record (DHR) shall be kept by BM at its premises for all Category
      A Products and for all [***] and shall be available to the FDA directly or
      confidentially through a third party for necessary regulatory inspections.
      If the aforementioned documents have to be filed at the FDA the costs of
      this filing shall be paid by GEN-PROBE. To the extent that BM reasonably
      incurs significant costs for complying with the requirements of this
      Section as to [***], the parties will negotiate in good faith to
      compensate BM for such costs and to define a reasonable time period for
      completion of such requirements.

9.2   If the applicable regulatory agencies request amendments of the
      documentation or design of the Products including but not limited to DHF,
      DMR and DHR, BM undertakes to use its reasonably best efforts to fulfill
      these requirements. Any such amendments shall be mutually agreed upon
      between GEN-PROBE and BM. The parties shall agree upon compensation to BM
      in connection with fulfilling the requirements of the amendments before
      any action is taken, unless such amendments are the result of BM's failure
      to comply with manufacturing standards requiring utilization of such
      manufacturing processes as are controlled and validated, with adequate
      records of the processes used. To the extent that adequate compensation
      for such proposed changes cannot be provided to BM by way of reasonable
      adjustment to the purchase price of the Products, the parties will
      negotiate in good faith for another form of payment to BM. If the parties
      are not able to agree on such compensation, either party may terminate
      this Agreement.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                    Page 10
<PAGE>
SECTION 10 INTELLECTUAL PROPERTY RIGHTS

10.1  The ownership of any and all intellectual property rights of BM as
      reflected in the Transformed Clone and BM's T7 RNA Polymerase shall remain
      with BM. BM recognizes that the Transformed Clone is a derivative of an
      original clone supplied to BM by GEN-PROBE and BM therefore agrees not to
      transfer the Transformed Clone to any other person or entity (with the
      exception of affiliates of BM or subcontractors appointed by BM and
      authorized by GEN-PROBE, which affiliates and subcontractors shall have
      the same secrecy obligations as the Parties with regard to the original
      GEN-PROBE clone and the Transformed Clone).

10.2  In the Event that claim of patent infringement is made against BM or any
      of its Affiliates, by any third party by reason of GEN-PROBE's sale or use
      of the Products in combination with GEN-PROBE technology, to the extent
      that the infringement is based upon the new combination product, GEN-PROBE
      hereby agrees to indemnify, defend and save each of them, harmless of and
      from and all liability, loss, cost, injury, damage, demand and expense
      (including, without limitation, reasonable attorney's fees) of any kind
      whatever arising out of, on account of, or in connection with such claim
      of infringement. Excepted from such hold harmless obligation shall be
      indirect or consequential damages whether or not based on negligence.

      In the event that claim of patent infringement is made against GEN-PROBE
      or any of its Affiliates, by any third party by reason of GEN-PROBE's sale
      or use of the Products, BM hereby agrees to indemnify, defend and hold
      GEN-PROBE, and its parents, subsidiaries, Affiliates, officers, directors,
      agents and employees, and each of them, harmless of and from any and all
      liability, loss, cost, injury, damage, demand and expense (including,
      without limitation, reasonable attorney's fees) of any kind whatsoever
      arising out of, on account of, or in connection with such claim of
      infringement. Excepted from such hold harmless obligation shall be
      indirect or consequential damages whether or not based on negligence.

10.3  BM and GEN-PROBE agree to give prompt written notice to the other of the
      commencement of any action, suit or proceeding for which the foregoing
      indemnification may be sought, and the other party, through counsel
      reasonably satisfactory to BM or GEN-PROBE, shall assume the defense
      thereof. It is agreed that the party claiming a right to indemnification
      shall be entitled to participate in any such action, suit or proceeding
      with counsel of its own choice, but at its own expense.

                                    Page 11
<PAGE>
SECTION 11 WARRANTY AND LIABILITY

11.1  BM hereby warrants that the Products will be produced in accordance with
      the applicable regulations and statutory requirements, will fully conform
      to the Product specifications listed in Attachment A hereto, and will be
      free from defects in materials or workmanship. BM's manufacturing
      processes shall meet the requirements of any manufacturing standards
      applicable to materials included or used in the manufacture of in vitro
      diagnostic products of like kind as GEN-PROBE's TMA products, but not less
      than such manufacturing processes as are controlled and validated, with
      adequate records of the processes used. If BM incurs additional costs in
      order to meet standards imposed after the Signing Date of this Agreement,
      the prices charged pursuant to Section 4 are subject to change to the
      extent necessary to compensate BM for such changes. To the extent that
      adequate compensation for such proposed changes cannot be provided to BM
      by way of reasonable adjustment to the purchase price of the Products, the
      parties will negotiate in good faith for another form of payment to BM. If
      the parties are not able to agree on such compensation, either party may
      terminate this Agreement.

      Beyond the warranties expressly stated herein, BM shall assume no warranty
      as to the fitness of the Products for the purpose intended by GEN-PROBE.

      THE FOREGOING WARRANTY SHALL BE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS
      OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WAY OF
      MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN NO CASE SHALL BM
      BE LIABLE FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES.

      The financial liability of BM in connection with its warranty obligations
      under this Section 11.1 shall be limited to the reimbursement or crediting
      of the price of the defective Products to GEN-PROBE or, where this may be
      agreed between the Parties hereto, to the supply of the Products in
      replacement for the defective Products. Nothing in this Section shall
      limit GEN-PROBE's rights under Section 11.2.

11.2  BM will defend, indemnify and hold harmless GEN-PROBE from any and all
      claims, liabilities or reasonable out-of-pocket expenses arising from or
      related to any and all claims and will pay all cost of damages finally
      awarded in any proceedings or any settlement made with BM's consent with
      respect to any claims for damages alleged to have been sustained as a
      result of BM's negligent acts or omissions. Excepted from such hold
      harmless obligation shall be indirect or consequential damages whether or
      not based on negligence.

                                     Page 12
<PAGE>
      GEN-PROBE will defend, indemnify and hold harmless BM from any and all
      claims, liabilities or reasonable out-of-pocket expenses arising from or
      related to any and all claims and will pay all cost of damages finally
      awarded in any proceedings or any settlement made with GEN-PROBE's consent
      with respect to any claims for damages alleged to have been sustained as a
      result of GEN-PROBE's negligent acts or omissions. Excepted from such hold
      harmless obligation shall be indirect or consequential damages whether or
      not based on negligence.

      [***]

11.3  Each party agrees to promptly give written notice to the other party of
      the commencement of any action, suit or proceeding for which
      indemnification may be sought, and the indemnifying party, through counsel
      reasonably satisfactory to the indemnified party shall assume the defense
      thereof. It is agreed, however, that the indemnified party shall be
      entitled to participate in any such action, suit or proceeding with
      counsel of its own choice, but at its own expense.

SECTION 12 SECRECY OBLIGATION

      Each party shall keep all information and know how communicated to it or
      otherwise obtained from the other party at any time during the term of
      this Agreement and in connection with this Agreement (including but not
      limited to know-how, technology, pricing, usage rates, and business
      projections) secret and confidential and shall not disclose the same or
      any part thereof to any third party. Excepted herefrom is information:

      a)    which is in the public domain at the time of disclosure,

      b)    which is published or otherwise becomes part of the public domain
            through no fault of the party receiving the information,

      c)    which was in the possession of the receiving party at the time of
            disclosure, as shown by prior written records, or becomes available
            from a third party who has the right to disclose it;

      d)    which is required to be communicated to authorities or customers for
            the purpose of sale of the Products, or

      e)    which has been independently developed by the receiving party at or
            before the date of disclosure.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 13

<PAGE>
SECTION 13 TERM AND TERMINATION

13.1  This Agreement becomes effective as of the date of signature of the last
      party to sign and shall remain in force for an initial period of ten (10)
      years from the execution of this Agreement. Thereafter the Agreement
      automatically prolongs for two (2) year terms if not terminated by one of
      the parties at the end of the initial period or prolongation period with
      twelve (12) months prior written notice.

13.2  In the event that either party fails or becomes unable to substantially
      perform any of the obligations or undertakings to be performed by it under
      this Agreement then the other party shall provide the defaulting party
      with written notification of such default. If such default or inability
      is not cured within ninety (90) days to the mutual satisfaction of both
      parties, then the non-defaulting party shall have the right to terminate
      this Agreement upon 15 days upon written notice. Notwithstanding the
      foregoing provisions, if BM's default is limited only to an inability to
      deliver, within ten (10) working days after the scheduled delivery date on
      the purchase order, any single Product, then GEN-PROBE shall be obligated
      to first use one-half of the then-available safety stock of that Product
      established pursuant to section 7.1 of this Agreement, and -- after using
      one-half of the safety stock of that Product -- then GEN-PROBE shall only
      have the right to partially terminate this Agreement as to the single
      Product which BM has failed to deliver.

13.3  Both parties shall have the right to terminate this Agreement forthwith in
      the event that the other party shall become bankrupt or insolvent, or make
      any arrangement with its creditors and/or a winding-up order is made and/
      or if its business shall be placed in the hands of a receiver, assignee or
      trustee, whether by the voluntary act or otherwise.

      All rights granted hereunder by BM to its intellectual property or
      confidential information under any title whatsoever, except for the rights
      set forth in Section 7.4 B and C, shall return to BM after termination or
      expiration of this Agreement.

13.4  After any termination of the Agreement (except for a termination by
      GEN-PROBE due to BM's failure to meet Product specifications or due to
      BM's intentional and willful default), GEN-PROBE shall purchase from BM
      the complete existing safety stock of the Products at the prices as agreed
      upon between BM and GEN-PROBE for the last full year in which The Products
      have been sold. BM shall provide the information described in Section 3.2
      for the safety stock Products at the time of the delivery of those
      Products. As to any Products which are kept as safety stocks at a
      GEN-PROBE facility, GEN-PROBE shall accept or reject such Products
      pursuant to Section 8 of this Agreement within 30 days of the initial
      delivery of such Products to GEN-PROBE for use as safety stock.

                                     Page 14
<PAGE>
13.5  Upon the termination of this Agreement, BM shall destroy all Transformed
      Clones. Upon the termination of this Agreement, Gen-Probe shall destroy
      all Transformed Clones except to the extent it has continuing rights with
      respect to the Transformed Clone under Section 7.4 of this Agreement.

13.6  The following provisions shall survive termination of this Agreement:
      Sections 4, 5, 7.4, 10, 11, 12, 13.4, 14 and 15.

SECTION 14 ARBITRATION

      Any controversy, claim or dispute existing out of or relating to this
      Agreement, or the breach thereof, shall be resolved by binding
      arbitration, with any proceedings or hearings to take place rendered by
      arbitration may be entered in any Court having jurisdiction. If parties do
      not agree upon location, the arbitrator shall determine the location. If
      arbitration is necessary pursuant to this paragraph, the Parties shall
      agree upon a single arbitrator. If the Parties are unable to agree on an
      arbitrator, then they will obtain nominations of three potential
      arbitrators from the International Chamber of Commerce of New York, USA
      and each party will have the right to strike one candidate's name from the
      list. The International Chamber of Commerce of New York, USA will then
      designate the arbitrator. Any arbitration award shall also include, but
      shall not be limited to, any and all court or arbitration costs, attorney
      fees and any other costs or charges reasonably necessary to adjudicate the
      controversy, in addition to any and all damages deemed fair by the
      arbitrator. Nothing contained herein shall deprive any party of his or her
      right to obtain injunctive or other equitable relief.

SECTION 15 GENERAL PROVISIONS

15.1  Entire Agreement

      This Agreement constitutes the entire understanding between the parties
      with respect to the subject matter hereof, and supersedes and replaces all
      prior agreements, understandings, writings and discussions between the
      parties relating to said subject matter, except as to any and all prior
      material transfer or confidential disclosure agreements between the
      parties, which are superseded only with respect to the Transformed Clone
      in the manner expressly set forth in Sections 1.4, 7.4, and 10.1.

                                     Page 15
<PAGE>
15.2  Amendments; Waivers

      This Agreement may be amended and any of its terms or conditions may be
      waived only by a written instrument executed by both parties, or, in the
      case of a waiver, by the party waiving compliance. The failure of either
      party at any time to require performance of any provision hereof shall in
      no manner affect its rights at a later time to enforce the same. No waiver
      by either party of any condition or term in any instance shall be
      construed as a further or continuing waiver of such condition or term or
      of another condition or term.

15.3  Successors and Assigns

      This Agreement shall be binding upon and inure to the benefit of and be
      enforceable by the parties hereto and their respective successors and
      permitted assigns. BM shall be entitled to assign this Agreement if
      necessary after the merger with Hoffmann-La Roche to its succeeding legal
      entity with the exception that no GEN-PROBE-designated proprietary
      information shall be disclosed to competing operating business units
      affiliated with BM, including Hoffman-La Roche.

15.4  Governing Law

      This Agreement will be in all events and for all purposes governed by, and
      construed in accordance with the law of the State of Indiana.

15.5  Severability

      The parties agree that if any part, term or provision of this Agreement
      shall be found illegal or in conflict with any valid controlling law, the
      validity of the remaining provisions shall not be affected thereby.

      In the event the legality of any provision of this Agreement is brought
      into question because of a decision by a Court of competent jurisdiction
      of any country in which this Agreement applies, GEN-PROBE and BM will
      negotiate in good faith in order to revise or delete the provision in
      question so as to comply with the decision of said Court.

      In the event that the terms and conditions of this Agreement are
      materially altered as a result of the preceding sub-paragraphs, the
      Parties shall re-negotiate the terms and conditions of this Agreement in
      order to resolve any inequities.

                                     Page 16
<PAGE>
15.6  Headings and titles in this Agreement are for convenience purposes only
      and shall not in any way influence the construction, performance and
      enforcement of any of its provisions.

15.7  Written Notices required to be given under this Agreement shall be
      considered duly given upon receipt by the addressee if mailed by first
      class registered mail with return receipt requested, postage prepaid and
      addressed as follows:

      If to BM:

         Boehringer Mannheim GmbH
         Legal Counsel, Biochemical Division
         Sandhofer Strasse 116
         68305 Mannheim
         Germany

If to GEN-PROBE:

         Gen-Probe Incorporated
         Attention: General Counsel
         10210 Genetic Center Drive
         San Diego, California, U.S.A. 92121-4362

15.8  Force Majeure

      In the event that either party is prevented from performing or is unable
      to perform any of its obligations due to any act of God, war, labor
      difficulties, riot, fire, flood, hurricane, wind storm, failure of public
      utilities, acts of default by common carriers, governmental laws, act or
      regulations (including withdrawal or suspension of governmental sale of
      Product), shortages of materials or any other occurrence beyond the
      control of the party affected thereby, if such party shall have used its
      best effort to avoid such occurrence, such party shall give notice to the
      other promptly in writing, and thereupon the affected party's performance
      shall be excused and the time for performance shall be extended for the
      period of the delay or inability to perform due to such occurrence;
      provided always that upon BM's inability to supply any Product, GEN-PROBE
      shall have the right, after using one-half of the safety stock of any
      affected Product(s), to obtain such Product(s) from an alternative source
      and to exercise its rights under section 7.4 if necessary.

                                     Page 17
<PAGE>
15.9  The following attachments to this Agreement are hereby incorporated into
      this Agreement by this reference and shall be considered integral parts of
      this Agreement.

Attachment A:   Specifications and Product
                Acceptance Criteria

Attachment B:   BM Product Pricing Schedule

Attachment C:   Annual Product Projections

      IN WITNESS WHEREOF, the parties have signed this Agreement, which shall be
effective on a date that it is signed by the last party to sign (the "Signing
Date").

Mannheim, Germany                        San Diego, California U.S.A.
March 5, 1998                            March 2, 1998

Boehringer Mannheim GmbH                 Gen-Probe Incorporated

By: /s/ FRED RUSH                        By: /s/ HENRY L. NORDHOFF
    ---------------------------              -----------------------------------
    Fred Rush                                Henry L. Nordhoff
    Senior Vice President                    President and
                                             Chief Executive Officer

By: /s/ JAN VAN DER VALK
    --------------------------
    Jan van der Valk
    Senior Director Legal Counsel

                                    Page 18
<PAGE>

              ATTACHMENT A: SPECIFICATIONS AND ACCEPTANCE CRITERIA

    [44 Pages of Specifications and Product Information Deleted Pursuant to
                        Confidential Treatment Request]

<PAGE>
                            Attachment B, Category A

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
                            Attachment B, Category B

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                  Attachment C

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}]]